Bexotegrast

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

Phase II clinical trials in primary sclerosing cholangitis: Making the most of every opportunity?

Assis DN, Hov JR

Phase II INTEGRIS-PSC trial of bexotegrast, an α(v)β(6)/α(v)β(1) integrin inhibitor, in primary sclerosing cholangitis.

Hirschfield GM, Kowdley KV, Trivedi PJ et al.

Dual α(v)β(6) and α(v)β(1) Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial.

Montesi SB, Cosgrove GP, Turner SM et al.

Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study.